New biologic drugs, such as monoclonal antibodies and immunotherapies in clinical development, designed to target metastatic colorectal cancer (CRC) and stimulate the immune system to destroy tumor cells are a significant ...
Aug 29, 2017
0
1
Clinical trial results presented in an oral abstract session 3:00pm Monday, June 5 at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 shows promising results for the addition of vemurafenib (anti-BRAF) ...
Jun 5, 2017
0
2
About 95 percent of colorectal cancers are considered "microsatellite stable" and very few of these cancers respond to immunotherapy, meaning that the vast majority of metastatic colorectal cancer patients are unable to benefit ...
Apr 3, 2017
0
0
A combination of two HER2-targeted therapies, trastuzumab (Herceptin) and lapatinib (Tykerb), showed clinical benefit in patients with heavily pretreated HER2-positive metastatic colorectal cancer, according to final results ...
Apr 3, 2017
0
1
Researchers at Uppsala University have identified gene mutations that are associated with the spread of metastases in colorectal cancer. The findings that have recently been published in the journal Cancer Research could ...
Jan 27, 2017
0
7
Patients with metastatic colorectal cancer may be able to lower the risk of the disease worsening, and improve their chances of survival, if they engage in moderate daily exercise, according to new research by investigators ...
Jan 18, 2017
0
1
New SWOG study results show significantly better outcomes for patients with a treatment-resistant form of metastatic colorectal cancer when the BRAF inhibitor vemurafenib is added to a standard treatment. The findings, for ...
Jan 18, 2017
0
3
(HealthDay)—Survival odds for colorectal cancer may depend on which side of the colon the primary tumor develops, according to a study released Wednesday during a media briefing that previewed some of the research to be ...
May 20, 2016
0
2
New research from the Canadian Cancer Trials Group (CCTG) has discovered that a new subset of patients with metastatic colorectal cancer could benefit from taking the drug cetuximab.
May 13, 2016
0
19
Cancer researchers have identified a marker that shows up in a blood test that determines which patients with colorectal cancer that has spread would benefit from receiving the drug cetuximab.
May 13, 2016
0
4
